The deficiency of 21-hydroxylase due to CYP21A2 pathogenic variants is a rather frequent disease with serious consequences, going from a real mortality risk to infertility and to milder symptoms, ...

Acute kidney injury (AKI) may progress to chronic kidney disease, and there is an urgent need for approaches that improve the limited regeneration of the renal tubules after AKI.

Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, United States ...

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) is expected to issue its quarterly earnings data on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.82) per share and ...

Agios Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of -$1.44 compared to the forecast of -$1.68. The company also ...

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

Lung metastases are a devastating reality for over half of cancer patients whose tumors spread beyond their initial sites. These secondary lung tumors develop in part because of unique conditions ...

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, is strongly induced in CD8 + T cells in solid cancer, the primary ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...